

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Borcherding et al.**

Examiner: **BERCH, Mark L.**

Application No.: **10/677,683**

Art Unit: **1624**

Filed: **October 2, 2003**

Title: **ACYL AND SULFONYL DERIVATIVES  
OF 6,9-DISUBSTITUTED 2-(TRANS-  
1,4-DIAMINOCYCLOHEXYL)-  
PURINES AND THEIR USE AS  
ANTIPROLIFERATIVE AGENTS**

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



---

George S. Jones, Reg. No. 38,508  
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3776  
Telefax (908) 231-2626  
sanofi-aventis Docket No. USA3960 US CNT



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **2****Complete if Known**

Application Number	10/677,683
Filing Date	October 2, 2003
First Named Inventor	BORCHERDING et al.
Group Art Unit	1624
Examiner Name	BERCH, Mark L.
Attorney Docket Number	USA3960 US CNT

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.	T <sup>3</sup>
		ANDRIKO et al., Reticulum Cell Neoplasms of Lymph Nodes: A Clinicopathologic Study of 11 Cases With Recognition of a New Subtype Derived From Fibroblastic Reticular Cells, Am J. of Surgical Pathology, Abstract	
		KNOCKAERT et al., Pharmacological inhibitors of cyclin-dependent kinases, Trends in Pharmacological Sciences, Vol. 23, No. 9, Sept. 2002, pp.417-425	
		SHERR et al., CDK inhibitors: positive and negative regulators of G1-phase progression, Genes & Dev. 1999, Vol. 13, pp. 1501-1512	

Examiner  
SignatureDate  
Considered<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.